Concert Pharmaceuticals Inc
F:73C
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Etga Group Ltd
TASE:ETGA
|
IL |
Concert Pharmaceuticals Inc
Note Receivable
Concert Pharmaceuticals Inc
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Concert Pharmaceuticals Inc
F:73C
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Concert Pharmaceuticals Inc
Glance View
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. The company is headquartered in Lexington, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2014-02-13. The firm is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The firm is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The firm is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.
